Comparing two ways of giving albumin for kidney injury in cirrhosis
Treatments studied
Part of Digestive system, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether giving albumin (a blood protein) in a personalized dose works better than a standard fixed dose for people with cirrhosis and sepsis-related acute kidney injury. The goal is to find a safer and more effective way to protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have cirrhosis and a sudden kidney injury caused by sepsis
- You are not already on dialysis or machine-based blood filtration
- You do not have severe shock needing strong blood pressure medicines
- You do not have a known heart disease with low pumping strength
- You do not have severe lung disease or need a ventilator
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a lower dose of albumin works as well as the standard dose for people with cirrhosis and a type of infection called spontaneous bacterial peritonitis (SBP). It aims to see if the low dose can protect kidney function while reducing side effects and costs.
This study tests whether giving a common fluid (albumin) early can help protect the kidneys in people with advanced liver disease who have a sudden kidney injury. It aims to see if this simple treatment can improve recovery and prevent the need for dialysis.
This trial tests whether giving albumin (a blood protein through an IV) can improve recovery after acute kidney injury in people who are in the ICU and need kidney support treatment. It mainly aims to help the kidneys bounce back better after this serious illness.
This trial tests whether giving albumin (a protein in your blood) after a liver transplant can help prevent or reduce kidney damage. It is for adults receiving their first liver-only transplant from a deceased donor.
This Phase 2 trial tests whether giving albumin together with enoxaparin (a blood thinner) can improve outcomes for people hospitalized with decompensated cirrhosis who are at high risk. It may help your recovery after certain serious liver-related complications and reduce the chance of poor outcomes.
This trial tests whether giving albumin through a vein is better than saline (salt water) for treating a sudden kidney injury in people with cirrhosis. The goal is to see which fluid helps the kidneys recover more effectively.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.